The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Lecanemab: Appropriate Use Recommendations
Open accessAbstract
Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology. Appropriate Use Recommendations (AURs) are intended to help guide the introduction of new therapies into real-world clinical practice. Community dwelling patients with AD differ from those participating in clinical trials. Administration of lecanemab at clinical trial sites by individuals experienced with monoclonal antibody therapy also differs from the community clinic-based administration of lecanemab. These AURs use clinical trial data as well as research and care information regarding AD to help clinicians administer lecanemab with optimal safety and opportunity for effectiveness. Safety and efficacy of lecanemab are known only for patients like those participating in the phase 2 and phase 3 lecanemab trials, and these AURs adhere closely to the inclusion and exclusion criteria of the trials. Adverse events may occur with lecanemab including amyloid related imaging abnormalities (ARIA) and infusion reactions. Monitoring guidelines for these events are detailed in this AUR. Most ARIA with lecanemab is asymptomatic, but a few cases are serious or, very rarely, fatal. Microhemorrhages and rare macrohemorrhages may occur in patients receiving lecanemab. Anticoagulation increases the risk of hemorrhage, and the AUR recommends that patients requiring anticoagulants not receive lecanemab until more data regarding this interaction are available. Patients who are apolipoprotein E ε4 (APOE4) gene carriers, especially APOE4 homozygotes, are at higher risk for ARIA, and the AUR recommends APOE genotyping to better inform risk discussions with patients who are lecanemab candidates. Clinician and institutional preparedness are mandatory for use of lecanemab, and protocols for management of serious events should be developed and implemented. Communication between clinicians and therapy candidates or those on therapy is a key element of good clinical practice for the use of lecanemab. Patients and their care partners must understand the potential benefits, the potential harms, and the monitoring requirements for treatment with this agent. Culture-specific communication and building of trust between clinicians and patients are the foundation for successful use of lecanemab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lecanemab has a boxed warning for serious and symptomatic ARIA and requires testing for APOE ε4 prior to initiation as homozygosity increases risk.(510)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [510]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently, anti-amyloid monoclonal antibodies require the confirmation of amyloid-β pathology from PET or CSF before initiating therapy45,46.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, although patients with early-stage AD may be candidates for anti-amyloid therapies15–17, the coexistence of pathology from other etiologies, such as VD, can increase the risk of amyloid-related imaging abnormalities18.”
From AI-based differential diagnosis of dementia etiologies on multimodal data (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The risk of developing these potentially serious adverse effects is higher in APOEε4 carriers, particularly homozygotes, and current recommendations are that patients are genotyped for APOE before starting these therapies to offer a balanced benefit–risk discussion190.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [190]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Plasma biomarkers may therefore have an important role in reducing the patient burden associated with the initiation of anti-amyloid-β therapies for AD, which at present require biomarker confirmation with PET or CSF, as well as serial magnetic resonance imaging to monitor for adverse events45,46.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“Individuals with two copies of the APOE‐e4 gene are at increased risk of developing ARIA.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“Accordingly, ApoE genotyping is now increasingly considered an important component of the pre-treatment work-up for anti-amyloid therapies [5, 8, 11, 12].”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Self-citationLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Self-citationMR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging
Fazekas, F., Chawluk, J. B., Alavi, A. A., Hurtig, H. I., & Zimmerman, R. A. (1987) · American Journal of Roentgenology · doi:10.2214/ajr.149.2.351 · Cited by 5,327
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Self-citation
Flagged first, then by citations
1 of the 62 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Irizarry M, van Dyck C, Sabbagh M, Bateman RJ, S. C, editors. Clarity AD: A phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer's disease. 15th Clinical Trials on Alzheimer's Disease Conference; 2022; San Francisco, CA USA.
Cited by
Sorted by citations
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
2025 Alzheimer's disease facts and figures
(2025) · Alzheimer s & Dementia · doi:10.1002/alz.70235 · Cited by 642
Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics
Hampel, H., Elhage, A., Cho, M., Apostolova, L. G., Nicoll, J. A. R., & Atri, A. (2023) · Brain · doi:10.1093/brain/awad188 · Cited by 412
Self-citationBlood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Palmqvist, S., Tideman, P., Mattsson-Carlgren, N., Schindler, S. E., Smith, R., Ossenkoppele, R., Calling, S., West, T., Monane, M., Verghese, P. B., et al. (2024) · JAMA · doi:10.1001/jama.2024.13855 · Cited by 416
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Cummings, J. L., Osse, A. M. L., Cammann, D., Powell, J., & Chen, J. (2023) · BioDrugs · doi:10.1007/s40259-023-00633-2 · Cited by 420
Self-citationSchindler, S. E., Galasko, D. R., Pereira, A. C., Rabinovici, G. D., Salloway, S., Suárez‐Calvet, M., Khachaturian, A. S., Mielke, M. M., Udeh‐Momoh, C. T., Weiss, J. O., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00977-5 · Cited by 348
Self-citationHampel, H., Hu, Y., Cummings, J., Mattke, S., Iwatsubo, T., Nakamura, A., Vellas, B., O’Bryant, S., Shaw, L. M., Cho, M., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.017 · Cited by 283
Self-citationDonanemab: Appropriate use recommendations
Rabinovici, G. D., Selkoe, D. J., Schindler, S. E., Aisen, P., Apostolova, L. G., Atri, A., Greenberg, S. M., Hendrix, S. B., Petersen, R. C., Weiner, M., et al. (2025) · The Journal of Prevention of Alzheimer's Disease · doi:10.1016/j.tjpad.2025.100150 · Cited by 278
Self-citationClinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Huang, L.-K., Kuan, Y.-C., Lin, H.-W., & Hu, C.-J. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00976-6 · Cited by 252
“The appropriate use recommendations (AURs) for lecanemab and aducanumab highlight the importance of patient selection, surveillance for adverse events, and clinician preparedness [44, 45].”
BackgroundBaker, L. D., Espeland, M. A., Whitmer, R. A., Snyder, H. M., Leng, X., Lovato, L., Papp, K. V., Yu, M., Kivipelto, M., Alexander, A. S., et al. (2025) · JAMA · doi:10.1001/jama.2025.12923 · Cited by 270
Self-citationDementia Prevention and Treatment
Reuben, D. B., Kremen, S. A., & Maust, D. T. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8522 · Cited by 225
Multifaceted roles of APOE in Alzheimer disease
Jackson, R. J., Hyman, B. T., & Serrano-Pozo, A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00988-2 · Cited by 193
Palmqvist, S., Whitson, H. E., Allen, L. A., Suárez‐Calvet, M., Galasko, D., Karikari, T. K., Okrahvi, H. R., Paczynski, M., Schindler, S. E., Teunissen, C. E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70535 · Cited by 220
Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
Honig, L. S., Sabbagh, M. N., van Dyck, C. H., Sperling, R. A., Hersch, S. M., Matta, A. P. C., Giorgi, L., Gee, M., Kanekiyo, M., Li, D., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01441-8 · Cited by 206
AI-based differential diagnosis of dementia etiologies on multimodal data
Xue, C., Kowshik, S. S., Lteif, D., Puducheri, S., Jasodanand, V. H., Zhou, O. T., Walia, A. S., Guney, O. B., Zhang, J. D., Poésy, S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03118-z · Cited by 182
Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging
Pittock, R. R., Aakre, J. A., Castillo, A. M., Ramanan, V. K., Kremers, W. K., Jack, C. R., Vemuri, P., Lowe, V. J., Knopman, D. S., Petersen, R. C., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207770 · Cited by 151
Self-citationRabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14338 · Cited by 163
Self-citationNew landscape of the diagnosis of Alzheimer’s disease
Frisoni, G. B., Hansson, O., Nichols, E., Garibotto, V., Schindler, S. E., van der Flier, W. M., Jessen, F., Villain, N., Arenaza-Urquijo, E. M., Crivelli, L., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01294-2 · Cited by 143
Self-citationChallenges in the practical implementation of blood biomarkers for Alzheimer’s disease
Schöll, M., Verberk, I. M. W., del Campo, M., Delaby, C., Therriault, J., Chong, J. R., Palmqvist, S., & Alcolea, D. A. (2024) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2024.07.013 · Cited by 150
Jönsson, L., Wimo, A., Handels, R., Johansson, G., Boada, M., Engelborghs, S., Frölich, L., Jessen, F., Kehoe, P. G., Kramberger, M., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100657 · Cited by 129
Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications
Doran, S. J., & Sawyer, R. P. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1326784 · Cited by 133
Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium
Collij, L. E., Bollack, A., Joie, R. L., Shekari, M., Bullich, S., Roé-Vellvé, N., Koglin, N., Jovalekic, A., García, D. V., Drzezga, A. E., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14336 · Cited by 130
Treatment for Alzheimer's disease
Fox, N. C., Belder, C. R. S., Ballard, C. G., Kales, H. C., Mummery, C. J., Caramelli, P., Ciccarelli, O., Frederiksen, K. S., Gómez‐Isla, T., Ismail, Z., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01329-7 · Cited by 137
Self-citationLecanemab Treatment in a Specialty Memory Clinic
Paczynski, M., Hofmann, A., Posey, Z. J., Gregersen, M., Rudman, M., Ellington, D., Aldinger, M., Musiek, E. S., Holtzman, D. M., Bateman, R. J., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.1232 · Cited by 116
Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability
Therriault, J., Janelidze, S., Benedet, A. L., Ashton, N. J., Arranz Martínez, J., Gonzalez-Escalante, A., Bellaver, B., Alcolea, D., Vrillon, A., Karim, H., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00731-y · Cited by 131
“Plasma biomarkers may therefore have an important role in reducing the patient burden associated with the initiation of anti-amyloid-β therapies for AD, which at present require biomarker confirmation with PET or CSF, as well as serial magnetic resonance imaging to monitor for adverse events 45,46 .”
Self-citationAntiamyloid Monoclonal Antibody Therapy for Alzheimer Disease
Ramanan, V. K., Armstrong, M. J., Choudhury, P., Coerver, K. A., Hamilton, R. H., Klein, B. C., Wolk, D. A., Wessels, S. R., & Jones, L. K. (2023) · Neurology · doi:10.1212/wnl.0000000000207757 · Cited by 120
Contemporary Management of Acute Ischemic Stroke
Ho, J. P., & Powers, W. J. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-050823-094312 · Cited by 117
Cogswell, P. M., Andrews, T. J., Barakos, J. A., Barkhof, F., Bash, S., Benayoun, M. D., Chiang, G. C.-Y., Franceschi, A. M., Jack, C. R., Pillai, J. J., et al. (2024) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8469 · Cited by 104
Passive anti-amyloid β immunotherapy in Alzheimer's disease—opportunities and challenges
Heneka, M. T., Morgan, D., & Jessen, F. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01883-x · Cited by 107
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 109
Self-citationRosenzweig, N., Kleemann, K. L., Rust, T., Carpenter, M., Grucci, M., Aronchik, M., Brouwer, N., Valenbreder, I., Cooper-Hohn, J., Iyer, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03122-3 · Cited by 90
Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms
Greenberg, S. M., Bax, F., & van Veluw, S. J. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-024-01053-8 · Cited by 107
Self-citationComparison of two plasma p-tau217 assays to detect and monitor Alzheimer’s pathology
Therriault, J., Ashton, N. J., Pola, I., Triana‐Baltzer, G., Brum, W. S., Molfetta, G. D., Arslan, B., Rahmouni, N., Tissot, C., Servaes, S., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105046 · Cited by 83
Jack, C. R., Arani, A., Borowski, B. J., Cash, D. M., Crawford, K., Das, S. R., DeCarli, C., Fletcher, E., Fox, N. C., Gunter, J. L., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14166 · Cited by 82
Self-citationAmyloid-Targeting Monoclonal Antibodies for Alzheimer Disease
Rabinovici, G. D., & La Joie, R. (2023) · JAMA · doi:10.1001/jama.2023.11703 · Cited by 80
Self-citationCummings, J. L. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00570 · Cited by 86
Self-citationAnti-amyloid therapies for Alzheimer disease: finally, good news for patients
Ramanan, V. K., & Day, G. S. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00637-0 · Cited by 78
Cho, H., Mundada, N. S., Apostolova, L. G., Carrillo, M. C., Shankar, R. P., Amuiri, A. N., Zeltzer, E., Windon, C., Soleimani‐Meigooni, D. N., Tanner, J. A., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13453 · Cited by 81
Self-citationRabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 87
Self-citationVillain, N., Planche, V., Lilamand, M., Cordonnier, C., Soto‐Martin, M., Mollion, H., Bombois, S., & Delrieu, J. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100094 · Cited by 87
Jeremic, D., Navarro‐López, J. D., & Jiménez‐Díaz, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102012 · Cited by 82
Noh, M., Kwon, H. S., Kwon, M., Nahm, M., Jin, H. K., Bae, J., & Kim, S. H. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00867-4 · Cited by 94
Chowdhury, S., & Chowdhury, N. S. (2023) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320231209839 · Cited by 76
Atri, A., Dickerson, B. C., Clevenger, C. K., Karlawish, J. H., Knopman, D. S., Lin, P., Norman, M., Onyike, C. U., Sano, M., Scanland, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14333 · Cited by 84
Self-citationApolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway
Narasimhan, S., Holtzman, D. M., Apostolova, L. G., Cruchaga, C., Masters, C. L., Hardy, J., Villemagne, V. L., Bell, J. S., Cho, M., & Hampel, H. J. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01669-5 · Cited by 70
Self-citationReview on anti-alzheimer drug development: approaches, challenges and perspectives
Abdallah, A. E. (2024) · RSC Advances · doi:10.1039/d3ra08333k · Cited by 63
Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier
Pardridge, W. M. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1227816 · Cited by 62
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 70
Self-citationAlkhalifa, A. E., Mokhlf, A. A., Ali, H., Al-Ghraiybah, N. F., & Syropoulou, V. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15090437 · Cited by 68
Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
Niimi, Y., Janelidze, S., Sato, K., Tomita, N., Tsukamoto, T., Kato, T., Yoshiyama, K., Kowa, H., Iwata, A., Ihara, R., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01469-w · Cited by 63
Anfray, A., Schaeffer, S., Hattori, Y., Santisteban, M. M., Casey, N., Wang, G., Strickland, M., Zhou, P., Holtzman, D. M., Anrather, J., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01757-6 · Cited by 53
Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center
Shields, L. B. E., Hust, H. S., Cooley, S. D., Cooper, G. E., Hart, R. N., Dennis, B. C., Freeman, S. W., Cain, J., Shang, W. Y., Wasz, K. M., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.159 · Cited by 57
Dickerson, B. C., Atri, A., Clevenger, C. K., Karlawish, J. H., Knopman, D. S., Lin, P., Norman, M., Onyike, C. U., Sano, M., Scanland, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14337 · Cited by 62
Self-citationDrug delivery strategies with lipid-based nanoparticles for Alzheimer’s disease treatment
Jang, Y.-J., Kang, S.-J., Park, H. S., Lee, D., Kim, J. H., Kim, J.-E., Kim, D., Chung, C., Yoon, J., & Bhang, S. H. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03109-3 · Cited by 64
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions
Rafii, M. S., & Aisen, P. S. S. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01123-5 · Cited by 62
Self-citationCurrent landscape of innovative drug development and regulatory support in China
Tan, R., Hua, H., Zhou, S., Yang, Z., Yang, C., Huang, G., Zeng, J., & Zhao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02267-y · Cited by 51
Lecanemab in clinical practice: real-world outcomes in early Alzheimer’s disease
Bregman, N., Nathan, T., Shir, D., Omer, N., Levy, M. H., David, A. B., Aizenstien, O., Lotan, E., Alcalay, Y., Awad, A. A., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01763-1 · Cited by 52
Prevalence of Alzheimer’s disease pathology in the community
Aarsland, D., Sunde, A. L., Tovar, D., Leuzy, A., Fladby, T., Zetterberg, H., Blennow, K., Tan, K., Santis, G. D., Yakoub, Y., et al. (2025) · Nature · doi:10.1038/s41586-025-09841-y · Cited by 75
Primary progressive aphasia: six questions in search of an answer
Belder, C. R. S., Marshall, C. R., Jiang, J., Mazzeo, S., Chokesuwattanaskul, A., Rohrer, J. D., Volkmer, A., Hardy, C. J. D., & Warren, J. D. (2023) · Journal of Neurology · doi:10.1007/s00415-023-12030-4 · Cited by 54
The advent of Alzheimer treatments will change the trajectory of human aging
Selkoe, D. J. (2024) · Nature Aging · doi:10.1038/s43587-024-00611-5 · Cited by 49
Self-citationTreatment of Alzheimer Disease
Geldmacher, D. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001503 · Cited by 51
Collij, L. E., Bischof, G. N., Altomare, D., Bader, I., Battle, M. R., García, D. V., Alves, I. L., Wolz, R., Gismondi, R., Stephens, A. W., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268119 · Cited by 48
Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care
Knopman, D. S., & Hershey, L. A. (2023) · Neurology · doi:10.1212/wnl.0000000000207438 · Cited by 47
Down Syndrome in a New Era for Alzheimer Disease
Rafii, M. S., & Fortea, J. (2023) · JAMA · doi:10.1001/jama.2023.22924 · Cited by 44
Sima, D. M., Phan, T. V., Eyndhoven, S. V., Vercruyssen, S., Magalhães, R. J. D. S., Liseune, A., Brys, A., Frenyo, P., Terzopoulos, V., Maes, C., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.55800 · Cited by 46
Dobson, R., Patterson, K., Malik, R., Mandal, U., Asif, H., Humphreys, R. A., Payne, M., O-charoenrat, E., Huzzey, L., Clare, A., et al. (2024) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-333468 · Cited by 44
Greenberg, S. M., Aparicio, H. J., Furie, K. L., Goyal, M. S., Hinman, J. D., Kozberg, M. G., Leonard, A., & Fisher, M. (2024) · Stroke · doi:10.1161/str.0000000000000480 · Cited by 44
Self-citationConcordance Between Amyloid-PET Quantification and Real-World Visual Reads
Zeltzer, E., Schonhaut, D. R., Mundada, N. S., Blazhenets, G., Mejía, J. A., Soleimani‐Meigooni, D. N., Cho, H., Ranasinghe, K. G., Windon, C., Yadollahikhales, G., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.2218 · Cited by 42
Self-citationSarazin, M., Lagarde, J., Haddad, I., de Souza, L. C., Bellier, B., Potier, M., Bottlaender, M., & Dorothée, G. (2024) · Nature Aging · doi:10.1038/s43587-024-00630-2 · Cited by 42
Hey, J. A., Abushakra, S. R., Blennow, K., Reiman, E. M., Hort, J., Prins, N. D., Sheardová, K., Kesslak, P. J., Shen, L. Z., Zhu, X., et al. (2024) · Drugs · doi:10.1007/s40265-024-02067-8 · Cited by 47
Factors Affecting Resilience and Prevention of Alzheimer's Disease and Related Dementias
Masurkar, A. V., Marsh, K., Morgan, B. E., Leitner, D., & Wısnıewskı, T. (2024) · Annals of Neurology · doi:10.1002/ana.27055 · Cited by 42
Tarawneh, R. M., & Pankratz, V. S. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01412-z · Cited by 42
BACE1 Inhibitors for Alzheimer’s Disease: Current Challenges and Future Perspectives
Coimbra, J. R. M., Resende, R., Custódio, J. B. A., Salvador, J. A. R., & Santos, A. E. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240146 · Cited by 43
2026 Alzheimer's disease facts and figures
(2026) · Alzheimer s & Dementia · doi:10.1002/alz.71345 · Cited by 69
Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology
Dhariwal, R., Jain, M., Mir, Y. R., Singh, A., Jain, B., Kumar, P., Tariq, M., Verma, D., Deshmukh, K., Yadav, V. K., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1522223 · Cited by 47
The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial
Mummery, C. J., Mayorga, A. J., Simmons, A., Chow, T. W., Burgess, B., Nguyen, T., 高晶晶, Budda, B., Park, L. Q., Gupta, R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04273-1 · Cited by 51
Self-citationBiskupiak, Z., Ha, V. V., Rohaj, A., & Bulaj, G. W. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020403 · Cited by 45
Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 40
From Lab Bench to Hope: Emerging Gene Therapies in Clinical Trials for Alzheimer’s Disease
Ortega, A., Chernicki, B. P., Ou, G., & Parmar, M. S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04285-3 · Cited by 41
Jeong, S. Y., Suh, C. H., Lim, J.-S., Shim, W. H., Heo, H., Choi, Y., Kim, H. S., Kim, S. J., & Lee, J.-H. (2025) · Neurology · doi:10.1212/wnl.0000000000213483 · Cited by 36
Lecanemab: Appropriate Use Recommendations by Korean Dementia Association
Park, K. H., Kim, G. H., Kim, C., Koh, S., Moon, S. Y., Park, Y. H., Seo, S. W., Yoon, B., Lim, J., Kim, B. C., et al. (2024) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2024.23.4.165 · Cited by 39
Clinical use of biomarkers in the era of Alzheimer's disease treatments
VandeVrede, L. A., & Schindler, S. E. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14201 · Cited by 36
Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology
Rafii, M. S., Schlachetzki, Z., Barroeta, I., Head, E., Fortea, J., & Ances, B. M. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00237-6 · Cited by 44
Ushering in a New Era of Alzheimer Disease Therapy
Widera, E., Brangman, S. A., & Chin, N. A. (2023) · JAMA · doi:10.1001/jama.2023.11701 · Cited by 36
Hickman, L. B., Stern, J. M., Silverman, D. H. S., Salamon, N., & Vossel, K. A. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1241638 · Cited by 37
Grill, J. D., Flournoy, C., Dhadda, S., Ernstrom, K. B., Sperling, R. A., Molina‐Henry, D. P., Tranotti, K., Harris, R., Kanekiyo, M., Gee, M., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26819 · Cited by 35
Self-citationThe Impact of Cognitive Impairment on Cardiovascular Disease
Jamil, Y., Krishnaswami, A., Orkaby, A. R., Stimmel, M. B., Brown, C. H., Mecca, A. P., Forman, D. E., Rich, M. W., Nanna, M. G., & Damluji, A. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.04.057 · Cited by 40
Lipid and lipoprotein metabolism in microglia: Alzheimer’s disease mechanisms and interventions
Sprenger, K. G., Lietzke, E. E., Melchior, J. T., & Bruce, K. D. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100872 · Cited by 42
The Latest Advances in the Diagnosis and Treatment of Dementia
Hafiz, R., Alajlani, L., Ali, A., Algarni, G. A., Aljurfi, H., Alammar, O. A. M., Ashqan, M. Y., & Alkhashan, A. Y. (2023) · Cureus · doi:10.7759/cureus.50522 · Cited by 41
New horizons in the diagnosis and management of Alzheimer’s Disease in older adults
Dolphin, H., Dyer, A. H., Morrison, L., Shenkin, S. D., Welsh, T. J., & Kennelly, S. (2024) · Age and Ageing · doi:10.1093/ageing/afae005 · Cited by 33
Zhao, T., Shi, Q., Zhang, X., & Zhang, T. (2024) · Journal of Retailing and Consumer Services · doi:10.1016/j.jretconser.2024.103886 · Cited by 33
Tran, J., Parekh, S., Rockcole, J., Wilson, D., & Parmar, M. S. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123001 · Cited by 35
Smith, E. E., Phillips, N. A., Feldman, H., BORRIE, M. J., Ganesh, A., Henri‐Bhargava, A., Desmarais, P., Frank, A., Badhwar, A., Barlow, L., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100068 · Cited by 42
Jiang, Y., Uhm, H., Ip, F. C., Ouyang, L., Lo, R. M. N., Cheng, E. Y. L., Cao, X., Tan, C. M. C., Law, B. C. H., Ortiz‐Romero, P., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13676 · Cited by 36
Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK
Laurell, A. A. S., Venkataraman, A. V., Schmidt, T., Montagnese, M., Mueller, C., Stewart, R. J., Lewis, J. R., Mundell, C., Isaacs, J. D., Krishnan, M. S., et al. (2024) · The British Journal of Psychiatry · doi:10.1192/bjp.2023.166 · Cited by 32
Bradshaw, A. C., & Georges, J. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.37 · Cited by 32
Apolipoprotein E Genetic Testing in a New Age of Alzheimer Disease Clinical Practice
Ritchie, M., Sajjadi, S. A., & Grill, J. D. (2024) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200230 · Cited by 32
The Impact of Anti-Amyloid Immunotherapies on Stroke Care
Bilodeau, P., Dickson, J. R., & Kozberg, M. G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051245 · Cited by 32
Metadata
- Authors
- Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., & Salloway, S.
- Affiliations
- Indiana University Indianapolis (US)
- University of California, San Francisco (US)
- Banner Health (US)
- University of Southern California (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Brown University (US)
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 10
- Issue
- 3
- Pages
- 362-377
- ISSN
- 2274-5807 (ISSN-L)
- PMC
- PMC10313141
- OpenAlex
- W4360591479
- Cited by
- 961
- References
- 62
- Citations by year
- 2026: 335 · 2025: 305 · 2024: 249 · 2023: 71
- FWCI
- 170.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Journal of Prevention of Alzheimer s Disease (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- Foundation for the National Institutes of Health (R35AG71476, U01NS093334, P20GM109025, P30AG072959, P30 AG010133, R01AG053798, R01 AG057739)
- Alzheimer's Association (P30 AG010133)
- Alzheimer's Drug Discovery Foundation (P20GM109025)
- Eli Lilly and Company (P20GM109025)
- Biogen (P20GM109025)
- University of Southern California (P20GM109025)
- Patient-Centered Outcomes Research Institute
- Alnylam Pharmaceuticals
- BioClinica (P20GM109025)
- Sunovion
- Buck Institute for Research on Aging
- Prothena
- University of Oxford
- Eisai (P20GM109025)
- Novo Nordisk
- Shionogi
- H. Lundbeck A/S (P20GM109025)
- Grifols
- Nestec
- National Institutes of Health (RD005665)
- Genentech (P20GM109025)
- Allergan
- Avid Radiopharmaceuticals
- National Institute on Aging (AG010133, P30AG010133, U01AG057195, NIA U01 AG057195, R01AG053798, P20AG068053, NIA P30 AG010133, R01AG057739, R35AG71476, P30AG072959, P30AG072980, R35AG071476)
- National Institute of General Medical Sciences (P20GM109025)
- National Institute of Neurological Disorders and Stroke (U01NS093334)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- lecanemab, Alzheimer's disease, amyloid-related imaging abnormalities, amyloid plaques, mild cognitive impairment, early Alzheimer's disease, bleeding risk, anticoagulation, infusion reactions, monoclonal antibody therapy, caregiver-patient communication, clinical preparedness
- MeSH terms
- Alzheimer Disease, Amyloid, Antibodies, Monoclonal, Humans, Apolipoprotein E4, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
